Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 10, 2011, Pages 4081-4086

  Benitez, Andrea Caballero ^a   Dai, Zhenpeng ^a   Mann, Henning H ^a   Reeves, Rebecca S ^a   Margineantu, Daciana H ^a   Gooley, Ted A ^a   Groh, Veronika ^a   Spies, Thomas ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Growth stimulation; Signal transduction

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; DNAX ACTIVATING PROTEIN 10; LYMPHOCYTE RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL KILLER GROUP 2 MEMBER D LYMPHOCYTE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL LINE, TUMOR; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 79952768178     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018603108     Document Type: Article

References (41)

1. Coudert JD, Held W (2006) The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 16:333-343. (Pubitemid 44311504)
2. Champsaur M, Lanier LL (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235:267-285.
3. Bauer S, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729.
4. Wu J, et al. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732.
5. Upshaw JL, Leibson PJ (2006) NKG2D-mediated activation of cytotoxic lymphocytes: Unique signaling pathways and distinct functional outcomes. Semin Immunol 18:167-175. (Pubitemid 43817560)
6. Lanier LL (2008) Up on the tightrope: Natural killer cell activation and inhibition. Nat Immunol 9:495-502.
7. Groh V, et al. (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96:6879-6884. (Pubitemid 29274978)
8. Eagle RA, Trowsdale J (2007) Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 7:737-744. (Pubitemid 47327391)
9. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521-11526. (Pubitemid 32928761)
10. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171. (Pubitemid 32867877)
11. Smyth MJ, et al. (2005) NKG2D function protects the host from tumor initiation. J Exp Med 202:583-588. (Pubitemid 41248410)
12. Guerra N, et al. (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28:571-580.
13. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738. (Pubitemid 35177960)
14. Groh V, Smythe K, Dai Z, Spies T (2006) Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 7:755-762. (Pubitemid 43905875)
15. Salih HR, Holdenrieder S, Steinle A (2008) Soluble NKG2D ligands: Prevalence, release, and functional impact. Front Biosci 13:3448-3456. (Pubitemid 351594695)
16. Li K, et al. (2009) Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: High expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58:641-652.
17. Duan X, et al. (2010) Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol, 10.1007/s12032-010-9480-9.
18. Sutherland CL, et al. (2002) UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 168:671-679. (Pubitemid 34049567)
19. Wan X, Helman LJ (2003) Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II- overexpressing rhabdomyosarcomas cells. Oncogene 22:8205-8211. (Pubitemid 37487311)
20. Meresse B, et al. (2004) Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21:357-366. (Pubitemid 39208337)
21. Roda-Navarro P, Reyburn HT (2009) The traffic of the NKG2D/Dap10 receptor complex during natural killer (NK) cell activation. J Biol Chem 284:16463-16472.
22. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533-2540. (Pubitemid 26192363)
23. Guy CT, et al. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582.
24. Gingrich JR, et al. (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57:4687-4691. (Pubitemid 27468967)
25. Kemp CJ (2005) Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol 15:460-473.
26. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M (2002) NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 3:1150-1155. (Pubitemid 35469699)
27. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501. (Pubitemid 37328931)
28. Ruggero D, Sonenberg N (2005) The Akt of translational control. Oncogene 24:7426-7434. (Pubitemid 41637982)
29. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22. (Pubitemid 47001784)
30. Wang L, Fraley CD, Faridi J, Kornberg A, Roth RA (2003) Inorganic polyphosphate stimulates mammalian TOR, a kinase involved in the proliferation of mammary cancer cells. Proc Natl Acad Sci USA 100:11249-11254.
31. Segovis CM, et al. (2009) PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion. J Immunol 182:6933-6942.
32. Normanno N, et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16. (Pubitemid 43199589)
33. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518. (Pubitemid 38868620)
34. Wu M, et al. (2007) Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 292:C125-C136. (Pubitemid 46115126)
35. Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627-5629.
36. Marusina AI, Burgess SJ, Pathmanathan I, Borrego F, Coligan JE (2008) Regulation of human DAP10 gene expression in NK and T cells by Ap-1 transcription factors. J Immunol 180:409-417.
37. Castriconi R, et al. (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100:4120-4125. (Pubitemid 36418167)
38. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE (2006) IL-21 downregulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol 176:1490-1497. (Pubitemid 43134292)
39. Krockenberger M, et al. (2008) Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180:7338-7348.
40. Guilloton F, et al. (2005) TNFalpha stimulates NKG2D-mediated lytic activity of acute myeloid leukemic cells. Leukemia 19:2206-2214. (Pubitemid 41741616)
41. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25:217-222. (Pubitemid 30394997)